S

Spravato

Product

by Janssen Pharmaceuticals, a Johnson & Johnson company

Heard in 2 episodes across 2 shows since Aug 2026

Spravato is a prescription esketamine nasal spray used under healthcare-professional supervision to treat adults with treatment-resistant depression, and in combination with an oral antidepressant for depressive symptoms in adults with major depressive disorder accompanied by acute suicidal ideation or behavior. It is administered in certified treatment settings with monitoring because of risks including sedation, dissociation, abuse, and misuse.

Episodes

2
across 2 shows

First heard

Aug 2026

Expert statements

1
1 positive

Episodes per month

Public PodLume episodes featuring it, over the last year.

Show the data
MonthEpisodes
Nov 20250
Dec 20250
Jan 20260
Feb 20260
Mar 20260
Apr 20260
May 20260
Jun 20260
Jul 20260
Aug 20261
Sep 20261
Oct 20260

What experts have said about Spravato

1 statement · 1 positive

  1. Anthony TennysonPositiveAug 26, 2026· The Sunday Roast

    Spravato is forecast to reach approximately a $2 billion run rate for J&J.

    “J&J Spravato is currently forecast, I think, to be about a $2 billion run rate business for J&J”

    Listen at 7:24

    Open the episode · S11 Ep100: Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNS
Filter the statements →

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Episodes

2 episodes featuring Spravato, newest first

Spravato · PodLume